Diagnosis and management of smouldering myeloma: A British Society for Haematology Good Practice Paper.

Autor: Hughes D; UCL Cancer Institute, University College London, London, UK., Yong K; UCL Cancer Institute, University College London, London, UK., Ramasamy K; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.; Oxford Translational Myeloma Centre, NDORMS, University of Oxford, Oxford, UK., Stern S; Epsom and St Helier University Hospitals NHS Trust, Sutton, UK., Boyle E; UCL Cancer Institute, University College London, London, UK., Ashcroft J; The Mid Yorkshire Teaching Hospitals NHS Trust, Wakefield, UK., Basheer F; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Rabin N; University College London Hospitals, London, UK., Pratt G; University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
Jazyk: angličtina
Zdroj: British journal of haematology [Br J Haematol] 2024 Apr; Vol. 204 (4), pp. 1193-1206. Date of Electronic Publication: 2024 Feb 23.
DOI: 10.1111/bjh.19333
Abstrakt: Multiple myeloma is a bone marrow-based plasma cell tumour that develops from asymptomatic pre-cursor conditions smouldering myeloma and monoclonal gammopathy of uncertain significance and all are characterised by the presence of a monoclonal protein in the blood. Diagnosis and distinction between these conditions is based on blood tests, the bone marrow biopsy and cross sectional imaging. There are various risk stratification models that group patients with smouldering myeloma into risk groups based on risk of progression to symptomatic disease. Management is mainly observational for patients with smouldering myeloma although clinical trials for high-risk disease may be available. Restaging is required if evidence for progression.
(© 2024 British Society for Haematology and John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: